BehaVR and Sumitomo Look to Help Patients Beat Anxiety with VR

BehaVR, an American therapeutic virtual reality company, has partnered with Japan-based Sumitomo Dainippon Pharma Co. to develop new prescription digital therapeutics (PDTs) for common mental health disorders.

The collaboration will see BehaVR leverage its VR therapy technology through Sumitomo’s expertise in developing novel prescriptions.

According to a recent press release, the partners plan to pursue FDA approval for three PDTs targeting three separate disorders: social anxiety, generalized anxiety disorder (GAD), and major depressive disorder.

These innovative solutions will all utilize VR technology and gamification structures to help patients prevent, treat, and manage these disorders.

BehaVR’s therapeutic offerings currently implement a proprietary protocol known as stress, anxiety, and fear extinction (S.A.F.E.), which is used to help patients build long-term resiliency skills.

Although specific details have not been revealed by the company, it is likely that their collaborative solutions will build on this already established protocol.